The FDA warns against using compounded drugs from Fullerton Wellness due to safety concerns.

The FDA has issued a safety alert regarding compounded drugs from Fullerton Wellness, LLC, in California, after discovering the use of non-sterile ingredients and inadequate sterilization processes. Patients are advised to stop using these drugs, which include semaglutide and tirzepatide, and consult their healthcare providers. Healthcare professionals should quarantine these products and refrain from administering them. There have been no reported adverse events, but any reactions should be reported to the FDA.

November 04, 2024
5 Articles